Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR17031 vs insulin glargine in type 2 diabetes inadequately controlled on basal insulin + metformin
CTR20241516Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of HR17031 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Change in HbA1c from baseline at week 26. Started Apr 2024; status: completed.
02
Drugs
HR17031
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20241516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241516.